Immuneering (IMRX) Research & Development (2020 - 2026)

Immuneering's Research & Development history runs 7 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 7.2% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $41.2 million (down 14.54% YoY), while the FY2025 annual figure was $42.0 million, down 12.33% from the prior year.
• Research & Development was $10.6 million for Q1 2026 at Immuneering, up from $9.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $14.9 million in Q4 2024 to a low of $8.0 million in Q2 2022.
• Historically, Research & Development has averaged $10.5 million across 5 years, with a median of $10.5 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 68.03% in 2022, then tumbled 37.71% in 2025.
• A 5-year view of Research & Development shows it stood at $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023, then gained by 24.74% to $14.9 million in 2024, then sank by 37.71% to $9.3 million in 2025, then grew by 15.03% to $10.6 million in 2026.
• The last three Research & Development figures came in at $10.6 million (Q1 2026), $9.3 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.